Join Clinical Trials in Virginia for Allergies

All Categories Medical Conditions » Allergies » Virginia

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2012
Elemental Formula Hypoallergenicity

Condition: Food Hypersensitivity
Interventions: Other: Amino Acid formula; Other: Commercially available Amino Acid Formula
Sponsors: Nestlé Nutrition Corporate; Nestlé Nutrition Corporate
Not yet recruiting - verified April 2012
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Matching Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)

Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Drug: Placebo Metered Dose Inhaler (MDI); Drug: Placebo Dry Powder Inhaler (DPI)
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012
Safety Study in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Primatene Mist; Drug: Epinephrine inhalation aerosol, HFA; Drug: epinephrine inhalation aerosol
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified November 2011
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Conditions: Perennial Allergic Rhinitis; PAR
Interventions: Drug: Ciclesonide nasal aerosol 37 mcg; Drug: ciclesonide nasal aerosol 74 mcg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified March 2012
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Long-acting Beta Agonist Step Down Study

Condition: Asthma
Interventions: Drug: Fluticasone/Salmeterol Diskus; Drug: Fluticasone/Salmeterol Diskus; Drug: Fluticasone Diskus
Sponsors: Johns Hopkins University; Johns Hopkins University; American Lung Association; GlaxoSmithKline
Recruiting - verified May 2012
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide; Drug: ecallantide; Drug: ecallantide; Drug: placebo
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
Bronchial Thermoplasty in Severe Persistent Asthma

Condition: Severe Asthma
Intervention: Device: Alair System
Sponsors: Asthmatx, Inc.; Asthmatx, Inc.; Boston Scientific Corporation
Recruiting - verified March 2012
Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Condition: Asthma
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012
Extensively Hydrolyzed Formula: Hypoallergenicity

Condition: Food Hypersensitivity
Interventions: Other: Extensively hydrolyzed, whey protein infant formula; Other: Extensively hydrolyzed, casein protein infant formula
Sponsors: Nestlé Nutrition Corporate; Nestlé Nutrition Corporate
Recruiting - verified March 2012
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

Condition: Asthma
Interventions: Drug: budesonide; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012
Study of Asthma and Nasal Steroids

Conditions: Asthma; Rhinitis; Sinusitis
Interventions: Drug: Mometasone Furoate monohydrate; Other: Placebo
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Conditions: Severe, Refractory Asthma; Airway Inflammation; Airflow Obstruction
Intervention: Drug: Pioglitazone
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index

Conditions: Deglutition Disorders; Esophageal Diseases; Eosinophilia
Intervention: Other: assessment of disease activity using the EEsAI
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Institute of Social and Preventive Medicine, University Bern; Dept. of Gastroenterology, Kantonsspital Olten, Olten; Luzerner Kantonsspital; Mayo Clinic Rochester, Minnesota, USA; University of Cincinnati; University of Colorado, Denver; Northwestern University of Chicago, Illinois, USA; Indiana University School of Medicine; Philadelphia University
Recruiting - verified March 2012
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified February 2012
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012